The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation


如何引用文章

全文:

详细

A combination of etoposide, doxorubicin and cisplatin plus mitotane (EPD-M) is the most effective regimen in patients with advanced adrenocortical carcinoma (ACC). Because in the Russian Federation mitotane is not registered, there are no publications about the effectiveness of EPD-M in the Russian patients. In the chemotherapy department of the NMITS of oncology named N.N.Blokhin of the Ministry of Health we conducted a retrospective analysis of the efficacy and tolerability of the EDP-M regimen as a first-line treatment in advanced ACC. We enrolled 24 patients with histologically confirmed ACC. Evaluation of the treatment effectiveness and toxicity was possible in 23 patients. Six patients (26%; 95% CI 8-44%) achieved a partial response, disease control rate was observed in 14 patients (61%; 95% CI 41-81%). Median time to progression was 4.9 months. Three patients (12.5%) were performed a radical surgical resection of residual disease after 6 cycles of chemotherapy. Then patients continued mitotane monotherapy after surgical resection. Treatment was well tolerated, with grade III and IV toxicities consisting of neutropenia in 8 (33%) patients, anemia in 1 (4%) patient, asthenia in 3 (12.5%) patients. The central neurotoxicity associated with mitotane, was observed in 2 (8.3%) patients. The EDP-M regimen is a well-tolerated and active regimen in patients with advanced ACC.

作者简介

A Kolomeytseva

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: almed2002@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

G Yemelyanova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: docgalina@mail.ru
канд. мед. наук, ассистент каф. онкологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

V Gorbunova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: veragorbounova@mail.ru
д-р мед. наук, проф., вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

N Orel

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: orel.nad@yandex.ru
д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

N Perevodchikova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: n.perevodchikova@mail.ru
д-р мед. наук, проф., вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V Bokhyan

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: b.vagan@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния хирургического №6 абдоминальной онкологии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A Fedenko

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: fedenko@eesg.ru
д-р мед. наук, зав. отд-нием химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

参考

  1. Kerkhofs T.M, Verhoeven R.H, Van der Zwan J.M. et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. EurJ Cancer 2013: epub April, 9th 2013.
  2. Kebebew E, Reiff E. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30 (5): 872-8.
  3. Lucas A, McDuffie L.A. et al. Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol 2016; 3 (2): 161-74
  4. Hescot S, Slama A, Lombes A. et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome C oxidase defect in human adrenocortical cells. EndocrRelat Cancer 2013; 20 (3): 371-81.
  5. Poli G, Guasti D, Rapizzi E. et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer2013; 20 (4): 537-50.
  6. Chortis V, Taylor A.E, Schneider P. et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98 (1): 161-71. 7- Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as et chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 274619-29.
  7. NCCN Clinical practice guidelines in oncology. Neuroendocrine tumors. Version 2.2017: National Comprehensive Cancer Network, 2017.
  8. Дедов И.И., Мельниченко Г.А, Бельцевич Д.Т. Опыт применения митотана в комплексном лечении адренокортикального рака. Рос. онкол. журн. 2016; 21 (6): 284-92.
  9. Коломейцева А.А, Горбунова В.А, Переводчикова Н.И. Современное состояние проблемы лечения адренокортикального рака. Современное состояние проблемы лечения адренокортикальногорака. Рос. онкол. журн. 2014; 19 (6): 44-8.
  10. Berruti A, Terzolo M, Sperone P. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 2005; 12 (3): 657-66.
  11. Fassnacht M, Terzolo M, Attolio B, FIRM-ACT Study Group et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366 (23): 2189-97.

版权所有 © Consilium Medicum, 2017

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##